Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis
STOCKHOLM — September 15, 2026. Umecrine Cognition today announced that the last patient has completed the final follow-up visit in the company's Phase 1b/2a study of golexanolone in patients with primary biliary cholangitis (PBC). The study evaluates the effect of golexanolone on fatigue and cogni…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.